Established, emerging and elusive molecular targets in the treatment of lung cancer. Issue 5 (14th February 2018)

• Record Type: Journal Article
• Authors: Gallant, Jean‐Nicolas; Lovly, Christine M
• Editors: Huntsman, David G; Ladanyi, Marc
• Is Part Of: Journal of pathology. Volume 244:Issue 5(2018)
• Page Start: 565
• Page End: 577
• Publication Date: 2018-02-14
• Subjects: lung cancer -- targeted therapy -- precision medicine -- EGFR -- ALK -- PD‐1 -- PD‐L1; Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.5038
• Languages: English
• ISSNs: 0022-3417

Abstract

Abstract: Although histological subtype still underlies tumour classification and treatment, the recognition that lung cancer is, largely, a genetic disease has prompted a push to reconfigure cancer taxonomies according to molecular criteria. In this review, we discuss established (e.g. EGFR, ALK, ROS1, and programmed cell death 1/programmed death‐ligand 1), emerging (e.g. MET, RET, and NTRK ) and elusive (e.g. TP53, KRAS, and MYC ) molecular targets in the treatment of lung cancer. We synthesize a large and rapidly growing body of literature regarding the discovery and therapeutic inhibition of these targets in lung cancer. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.